Rajesh Mukthavaram

Targeting and depletion of circulating leukocytes and cancer cells by lipophilic antibody-modified erythrocytes.

Published in Journal of Controlled Release

There is a great interest in targeting and selective ablation of populations of circulating cells for research or therapeutic purposes. Red blood cells (RBCs) are readily available and fully biocompatible long-circulating intravascular carriers (natural life is 120days) that are amenable to chemical modifications, drug loading and reinjection. Here...

Mitochondrial p32 is upregulated in Myc expressing brain cancers and mediates glutamine addiction.

Published in Oncotarget

Metabolic reprogramming is a key feature of tumorigenesis that is controlled by oncogenes. Enhanced utilization of glucose and glutamine are the best-established hallmarks of tumor metabolism. The oncogene c-Myc is one of the major players responsible for this metabolic alteration. However, the molecular mechanisms involved in Myc-induced metabolic...

Novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs.

Published in Journal of Translational Medicine